Jasmine Zain is a Hematologist and a Hematologist Oncology expert in Duarte, California. Zain has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Anaplastic Large Cell Lymphoma. She is also highly rated in 24 other conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Transplant, and Bone Marrow Aspiration.
Robert Chen is a Hematologist and a Hematologist Oncology expert in Los Angeles, California. Chen has been practicing medicine for over 21 years and is rated as an Elite expert by MediFind in the treatment of Anaplastic Large Cell Lymphoma. He is also highly rated in 19 other conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.
Andrei Shustov is a Hematologist Oncology specialist and an Oncologist in Seattle, Washington. Shustov has been practicing medicine for over 30 years and is rated as an Elite expert by MediFind in the treatment of Anaplastic Large Cell Lymphoma. He is also highly rated in 29 other conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Shustov is currently accepting new patients.
Summary: This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus carrying the human NIS and IFN beta genes (VSV-hIFNbeta-sodium iodide symporter [NIS]) with or without ruxolitinib phosphate in treating patients with multiple myeloma, acute myeloid leukemia, or T-cell lymphoma that has come back or does not respond to treatment. A virus, called VSV-hIFNbeta-NIS, w...
Summary: The purpose of this survey is to examine the safety of adult patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL) (excluding anaplastic large cell lymphoma (ALCL)) and pediatric patients with relapsed or refractory CD30-positive PTCL or Hodgkin lymphoma (HL) in the actual use of on concomitant Brentuximab Vedotin in routine clinical practice.
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center